More efficient ways of assessing treatments for neglected tropical diseases are required: Innovative study designs, new endpoints, and markers of effects

PLoS Neglected Tropical Diseases

Volumn 6, Issue 5, 2012, Pages

  Olliaro, Piero ^a,b   Vaillant, Michel T ^c   Sundar, Shyam ^d   Balasegaram, Manica ^e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d BANARAS HINDU UNIVERSITY   (India)

^e Drugs for Neglected Diseases initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; ANTIPROTOZOAL AGENT; BIOLOGICAL MARKER;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CHAGAS DISEASE; DIAGNOSTIC TEST; DRUG EFFICACY; HUMAN; MALARIA; NEGLECTED DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; STUDY DESIGN; TREATMENT OUTCOME; TRIANGULAR TEST; TROPICAL DISEASE; TUBERCULOSIS; VISCERAL LEISHMANIASIS; CLINICAL TRIAL (TOPIC); MEDICAL RESEARCH; METHODOLOGY; REVIEW; STANDARD; TROPIC CLIMATE;

ANTIPROTOZOAL AGENTS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; LEISHMANIASIS, VISCERAL; NEGLECTED DISEASES; TREATMENT OUTCOME; TROPICAL CLIMATE;

EID: 84863669384     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001545     Document Type: Article

References (19)

1. Sebille V, Bellissant E, (2003) Sequential methods and group sequential designs for comparative clinical trials. Fundam Clin Pharmacol 17: 505-516.
2. Whitehead J, Jones DR, (1979) The analysis of sequential clinical trials. Biometrika 66: 443-452.
3. Whitehead J, (1997) The design and analysis of sequential clinical trials, Revised; Wiley, editor. Chichester.
4. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, et al. (1976) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34: 585-612.
5. Pocock SJ, (1977) Group sequential methods in the design and analysis of clinical trials. Biometrika 64: 191-199.
6. O'Brien PC, Fleming TR, (1979) A multiple testing procedure for clinical trials. Biometrics 35: 549-556.
7. Lan KKG, De Mets DL, (1983) Discrete sequential boundaries for clinical trials. Biometrika 70: 659-663.
8. Wang SK, Tsiatis AA, (1987) Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 43: 193-199.
9. Pampallona S, Tsiatis A, (1994) Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plann Inf 42: 19-35.
10. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, et al. (2008) New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 47: 1000-1006.
11. Seifert K, Croft SL, (2006) In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 50: 73-79.
12. Brindle R, Odhiambo J, Mitchison D, (2001) Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 1: 2.
13. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, et al. (2000) A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45: 859-870.
14. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12: 128-138.
15. Nunn AJ, Phillips PP, Mitchison DA, (2010) Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 14: 241-242.
16. Nunn AJ, Phillips PP, Gillespie SH, (2008) Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) 88 (Suppl 1): S85-92.
17. Davies GR, Phillips PP, Nunn AJ, (2007) Biomarkers and surrogate end points in clinical trials of tuberculosis treatment. J Infect Dis 196: 648-649.
18. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, et al. (2004) In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48: 4271-4280.
19. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, et al. (2010) In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201: 570-579.